Pharma/Biotech Update: Baxter Reveals Trial Results for vWD Drug

For those suffering from von Willebrand Disease (vWD) a new pharmaceutical option may be available to you at the beginning of next year. A recent article from ZACKS announced that Baxter’s vWD drug BAX 111 reported top-line results from its “Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics.” BAX 111 is a recombinant von Willebrand factor  that is being studied for the treatment of bleeding episodes in patients with von Willebrand Disease and is the first recombinant treatment in clinical development for vWD.  It is estimated that 1 in every 100-1,000 people in the United States have vWD and it is considered the most common type of inherited bleeding disorder.

Currently, pharmaceutical options for vWD include the following:
-Alphanate – Grifols
-Stimate and Humate P – CSL Behring
-Wilate – Octapharma

With this news, Baxter has the intention to file for the U.S. approval of the drug before the end of 2014. Based on the trial results, Baxter will also be looking to pursue a study of BAX 111 in a prophylaxis treatment setting before the end of the year as well. Stay tuned with WeBleed as more information becomes available on BAX 111 down the road.

Photo Credit – Baxter Pharmaceuticals

webleed.org – your source for bleeding news!